Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults.
Takaaki KonumaJun OoiMaki Monna-OiwaMasamichi IsobeAkira TomonariSeiko KatoTohru IsekiYasuhito NannyaArinobu TojoSatoshi TakahashiPublished in: Leukemia & lymphoma (2021)
Comparative studies between total body irradiation (TBI)-based and busulfan-based myeloablative conditioning (MAC) regimens for cord blood transplantation (CBT) have been limited. We retrospectively analyzed the results of single-unit CBT in 333 adult patients who received either TBI-based ( n = 258) or busulfan-based ( n = 75) MAC regimens at our institute. After adjusting for significant variables in the univariate analysis, there were no significant differences in neutrophil recovery (hazard ratio (HR), 0.88; p = .460), grade III-IV acute graft-versus-host disease (GVHD) (HR: 1.40, p = .410), extensive chronic GVHD (HR: 0.73, p = .380), relapse (HR: 0.61, p = .270), non-relapse mortality (HR: 1.38, p = .420), overall survival (HR: 1.18, p = .637), or event-free survival (HR: 1.08, p = .773), although platelet recovery was lower with marginal significance for the busulfan-based regimen (HR: 0.67, p = .068). In subgroup analysis, TBI-based regimens were superior to busulfan-based regimens in terms of survival for acute lymphoblastic leukemia, but not for myeloid malignancies. Further investigation is warranted even for CBT.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- free survival
- cord blood
- acute lymphoblastic leukemia
- acute myeloid leukemia
- traumatic brain injury
- stem cell transplantation
- clinical trial
- randomized controlled trial
- stem cells
- dendritic cells
- type diabetes
- mesenchymal stem cells
- radiation therapy
- intensive care unit
- drug induced
- mild traumatic brain injury
- radiation induced